Meptid 200 mg Film-Coated Tablets

  • Name:

    Meptid 200 mg Film-Coated Tablets

  • Company:
    info
  • Active Ingredients:

    Meptazinol hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 22/09/17

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 5/8/2015
print

Print ViewKeyword Search SmPC

Almirall Limited

Almirall Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Almogran 12.5 mg Film-coated tablet Active Ingredients Almotriptan D, L-hydrogen malate
Medicine Name Meptid 100 mg/ml Solution for Injection Active Ingredients Meptazinol hydrochloride
Medicine Name Meptid 200 mg Film-Coated Tablets Active Ingredients Meptazinol hydrochloride
Medicine Name Skilarence 30 mg gastro-resistant tablets Active Ingredients Dimethyl fumarate
Medicine Name Skilarence 30 mg, 120 mg gastro-resisistant tablets Active Ingredients Dimethyl fumarate
Medicine Name Solaraze 3% Gel Active Ingredients Diclofenac Sodium
Medicine Name Vaniqa 11.5% cream Active Ingredients Eflornithine hydrochloride monohydrate
1 - 0 of 7 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 22 September 2017 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 22 September 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 August 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In section 4.8 Addition of QRD ADR reporting statement.

Updated on 5 August 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 26 March 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 11 March 2015 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2
Correction of Sunset Yellow content to 1.47 mg.

Section 6.1
Change of excipients of tablet coating - removal of Opaspray

Updated on 17 March 2011 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

  • section 1 for the tablet updated to include the full pharmaceutical form
·         section 2 updated in line with QRD
·        section 4.3 updated to strengthen the safety statements already under sections 4.4 and 4.5 namely contraindicating use during an asthma attacks and for patients on MAOIs and for 14 days after stopping MAOIs
·        section 4.4 updated by deleting the cautionary statement regarding MAOIs as this is now under section 4.3
·        section 4.5 updated with minor rewording
·        section 4.8 updated by ranking undesirable events under headings of frequency using the following convention: very common (≥ 1/10); common (≥1/100 to ≤1/10); uncommon (≥1/1,000 to ≤1/100); rare (≥1/10,000 to ≤1/1,000); very rare (≤1/10,000); not known (cannot be estimated from the available data).  This was purely a formatting request by the IMB; where within section 4.8, it was written that these were the "most commonly reported adverse reactions", these AEs were slotted under the tabular heading very common and those detailed as uncommon were slotted under the uncommon tabular heading under the relevant system organ class; "occassional reports" were re-classified as very rare reports.   
section 7 updated with change of name of MAH from "Laboratorios Almirall SA" to Almirall SA

Updated on 16 March 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to appearance of the medicine

Updated on 30 June 2009 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 18 June 2009 PIL

Reasons for updating

  • New PIL for new product